Head to head
Indivior vs Takeda Pharmaceutical
Side-by-side on the measures that matter, with a plain-English read. Full detail: INDV · TAK
INDV
Indivior
36.13+0.64%
1-year price shape — +52% over the period
Quant Rating B · 86/100
vs
TAK
Takeda Pharmaceutical
18.37+1.49%
1-year price shape — +29% over the period
Quant Rating C · 70/100
1-year performance, rebased to 100
Indivior edges it on the scoreable measures. Indivior has the highest Quant Rating (86); Indivior has done best over the past year (+52%); Indivior earns the most per share.
| INDV | TAK | |
|---|---|---|
| Snapshot | ||
| Sector | Drug Manufacturers - Specialty & Generic | -- |
| Last price | 36.13 | 18.37 |
| Change today | +0.64% | +1.49% |
| 1-year return | +52.3% | +29.2% |
| Market cap | $4.26B | $58.68B |
| 52-week range | 23.55 – 42.81 | 12.77 – 19.10 |
| Valuation | ||
| P/E (TTM) | 12.95 | -55.67 |
| P/E percentile, own 5-yr range | 50th | 4th |
| P/B | -20.60 | 1.23 |
| Dividend yield | 0.00% | 3.26% |
| Profitability & growth | ||
| EPS (TTM) | 1.64 | -0.31 |
| Net profit (TTM) | $193.57M | $-977.54M |
| Revenue (TTM) | $1.33B | $4.62T |
| Revenue growth (YoY) | +13.6% | +10.2% |
| Gross margin | 82.0% | 65.5% |
| Operating margin | 31.9% | 10.4% |
| Net margin | 26.7% | -3.5% |
| Free cash flow (TTM) | $-111.00M | $626.68B |
| Ownership & sentiment | ||
| Institutional ownership | 102.5% | 51.5% |
| Insider activity (12mo) | 39 buy / 11 sell | 22 buy / 28 sell |
| Short interest (% of float) | 9.5% | 0.1% |
| Analyst consensus | 100% buy (3) | 100% buy (1) |
| Analyst price target | $46 (+26%) | $43 (+134%) |
| StockVane view | ||
| StockVane Quant Rating | B (86) | C (70) |
| Company | ||
| Employees | 838 | 47,029 |
| Founded | 2014 | 1781 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.